{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-026724","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2024-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.342311+00:00","generated_at":"2026-05-31T21:58:48.108119+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Oragenics develops improved intranasal formulation for concussion drug ONP-002","bullets":["New formulation of ONP-002 designed to enhance brain uptake via nasal cavity, potentially reducing concussion symptoms.","Oragenics reports increased final dose levels and improved intranasal adhesion for longer absorption times.","Phase II study in concussed patients being planned to assess safety, feasibility, and effectiveness using blood biomarkers.","Concussion is a serious unmet need with 69 million cases annually worldwide; leads to long-term disability in up to 20%."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-026724","json":"https://secwatch.observer/filing/0001493152-24-026724.json","markdown":"https://secwatch.observer/filing/0001493152-24-026724.md","text":"https://secwatch.observer/filing/0001493152-24-026724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224026724/0001493152-24-026724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224026724/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:58:48.108119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}